CGeneTech (Suzhou) Co Ltd, a biotech company in SIP, announced its listing on the National Equities Exchange and Quotations (NEEQ, the New Third Board) on Sept 25.
As a commercial-stage biotech company, CGeneTech has established a pipeline covering drugs for lowering blood sugar and treating cancers and autoimmune diseases. Its new DPP-4 (dipeptidyl peptidase 4) inhibitor has been put into market for use in treatment of type 2 diabetes mellitus.
The listing on the New Third Board is expected to accelerate the clinical trials and commercialization of the company’s drug candidates.
September 25, 2025
